Real-world annualized relapse rates from contemporary multiple sclerosis clinics in the UK: a retrospective multicentre cohort study

[1]  T. Ishii,et al.  Calculating and Comparing the Annualized Relapse Rate and Estimating the Confidence Interval in Relapsing Neurological Diseases , 2022, Frontiers in Neurology.

[2]  M. Sormani,et al.  Estimation of sample size in randomized controlled trials in multiple sclerosis studying annualized relapse rates: A systematic review , 2021, Multiple sclerosis.

[3]  F. Guillemin,et al.  Clinical and radiological activity of secondary progressive multiple sclerosis in a population‐based cohort , 2021, European journal of neurology.

[4]  N. Schur,et al.  Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Disease in Switzerland , 2021, PharmacoEconomics.

[5]  S. Chaplin.  Siponimod for treating secondary progressive multiple sclerosis , 2020, The Prescriber.

[6]  Jeffrey A. Cohen,et al.  Ofatumumab versus Teriflunomide in Multiple Sclerosis. , 2020, The New England journal of medicine.

[7]  Yanli Zhang,et al.  Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing–remitting multiple sclerosis: a systematic review and network meta-analysis , 2019, Journal of Neurology.

[8]  T. Nazareth,et al.  Relapse prevalence, symptoms, and health care engagement: patient insights from the Multiple Sclerosis in America 2017 survey. , 2018, Multiple sclerosis and related disorders.

[9]  Bainan Xu,et al.  Efficacy and safety of monoclonal antibody therapies for relapsing remitting multiple sclerosis: A network meta-analysis. , 2018, Multiple sclerosis and related disorders.

[10]  Ludwig Kappos,et al.  Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study , 2018, The Lancet.

[11]  David H. Miller,et al.  Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria , 2017, The Lancet Neurology.

[12]  N. Robertson,et al.  How to run a multiple sclerosis relapse clinic , 2015, Practical Neurology.

[13]  T. Kalincik.  Multiple Sclerosis Relapses: Epidemiology, Outcomes and Management. A Systematic Review , 2015, Neuroepidemiology.

[14]  F. Jacques.  Defining the clinical course of multiple sclerosis: The 2013 revisions , 2015, Neurology.

[15]  M. Duddy,et al.  The UK patient experience of relapse in Multiple Sclerosis treated with first disease modifying therapies. , 2014, Multiple sclerosis and related disorders.

[16]  A. Waldman,et al.  Outcome Measures in Relapsing-Remitting Multiple Sclerosis: Capturing Disability and Disease Progression in Clinical Trials , 2014, Multiple sclerosis international.

[17]  T. Friede,et al.  Explaining temporal trends in annualised relapse rates in placebo groups of randomised controlled trials in relapsing multiple sclerosis: systematic review and meta-regression , 2013, Multiple sclerosis.

[18]  Roland Martin,et al.  Placebo Cohorts in Phase-3 MS Treatment Trials – Predictors for On-Trial Disease Activity 1990-2010 Based on a Meta-Analysis and Individual Case Data , 2012, PloS one.

[19]  Richard Nicholas,et al.  Time-patterns of annualized relapse rates in randomized placebo-controlled clinical trials in relapsing multiple sclerosis: A systematic review and meta-analysis , 2012, Multiple sclerosis.

[20]  Richard Nicholas,et al.  Trends in annualized relapse rates in relapsing–remitting multiple sclerosis and consequences for clinical trial design , 2011, Multiple sclerosis.

[21]  M. Sormani,et al.  Assessing changes in relapse rates in multiple sclerosis , 2010, Multiple sclerosis.

[22]  Yinshan Zhao,et al.  Impact of multiple sclerosis relapses on progression diminishes with time , 2009, Neurology.

[23]  Yinshan Zhao,et al.  Relapses in multiple sclerosis are age- and time-dependent , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[24]  D. Paty,et al.  Interferon beta-1b in secondary progressive MS , 2004, Neurology.

[25]  D. Silberberg,et al.  New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.